NONOF - Novo's Ozempic to face copycats as Chinese firm seeks approval for biosimilar
2024-04-03 07:01:03 ET
More on Novo Nordisk
- Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront
- Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified
- Novo Nordisk, A Very Healthy Pharma Stalwart
- CVS, Elevance Health to cover Novo Nordisk’s Wegovy: WSJ
- Sen. Sanders goes after Novo Nordisk on a study on Ozempic low manufacture cost